Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Clin Trials. 2024 Apr 9;21(3):322–330. doi: 10.1177/17407745231221152

Figure 2.

Figure 2.

Cumulative incidence of dose limiting toxicities (DLT) in the simulation scenario for dose level 2, within a 16-week follow-up window. Cumulative incidence is plotted according to the shape of DLT hazard, given a common value of 25% at week 16. t refers to the time since enrollment, in weeks.